Literature DB >> 29084631

Hazardous alcohol use among patients with schizophrenia and depression.

Mythily Subramaniam1, Mithila Valli Mahesh2, Chao Xu Peh2, Junda Tan2, Restria Fauziana2, Pratika Satghare2, Bhanu Gupta3, Kandasami Gomathinayagam4, Siow Ann Chong2.   

Abstract

AIMS: The current study aimed to 1) report the prevalence of hazardous alcohol use in an outpatient population among those with schizophrenia and depressive disorders, 2) assess the sociodemographic and clinical correlates of hazardous alcohol use, 3) examine the association of hazardous alcohol use with severity of depression, anxiety and smoking, and 4) assess the association of hazardous alcohol use with quality of life.
METHODS: Three hundred ten outpatients seeking treatment at a tertiary psychiatric institute with a diagnosis of either schizophrenia spectrum disorder or depressive disorder were included in the study. Patients were assessed for hazardous alcohol use using the Alcohol Use Disorders Identification Test. Information on sociodemographic correlates, clinical history, severity of symptoms of depression and anxiety, as well as quality of life (QOL) was collected.
RESULTS: The overall prevalence of hazardous alcohol use among the sample was 12.6%. The prevalence of hazardous alcohol use among patients with depression and schizophrenia was 18.8% and 6.4%, respectively. Compared to those who were students, patients who were gainfully employed or unemployed were more likely to engage in hazardous alcohol use (Odds Ratio (OR) = 5.5 and 7.7, respectively). Patients with depression compared to those with schizophrenia (OR = 11.1) and those who were current smokers compared to those who had never smoked (OR = 14.5) were more likely to engage in hazardous alcohol use. Hazardous alcohol use was associated with lower QOL in the physical health domain (p = 0.002).
CONCLUSION: Given the significant prevalence of hazardous alcohol use in this population, routine screening for hazardous alcohol use and brief interventions could be an effective way of managing this comorbidity. There is a need to develop and evaluate culturally appropriate brief interventions based on patient preference in this setting.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol use disorders identification test; Asian; Depression; Hazardous alcohol use; Schizophrenia

Mesh:

Year:  2017        PMID: 29084631     DOI: 10.1016/j.alcohol.2017.07.008

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  10 in total

1.  Comparison of Hypomanic Symptoms Between Bipolar I and Bipolar II Disorders: A Network Perspective.

Authors:  Wei Bai; Yuan Feng; Sha Sha; Qinge Zhang; Teris Cheung; Dexing Zhang; Zhaohui Su; Chee H Ng; Yu-Tao Xiang
Journal:  Front Psychiatry       Date:  2022-05-12       Impact factor: 5.435

2.  A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis.

Authors:  Jacob Cookey; Jacob McGavin; Candice E Crocker; Kara Matheson; Sherry H Stewart; Philip G Tibbo
Journal:  Can J Psychiatry       Date:  2020-02-04       Impact factor: 4.356

3.  Hazardous alcohol use in a sample of first episode psychosis patients in Singapore.

Authors:  Laxman Cetty; Shazana Shahwan; Pratika Satghare; Fiona Devi; Boon Yiang Chua; Swapna Verma; Helen Lee; Siow Ann Chong; Mythily Subramaniam
Journal:  BMC Psychiatry       Date:  2019-03-15       Impact factor: 3.630

4.  Tracking the mental health of a nation: prevalence and correlates of mental disorders in the second Singapore mental health study.

Authors:  M Subramaniam; E Abdin; J A Vaingankar; S Shafie; B Y Chua; R Sambasivam; Y J Zhang; S Shahwan; S Chang; H C Chua; S Verma; L James; K W Kwok; D Heng; S A Chong
Journal:  Epidemiol Psychiatr Sci       Date:  2019-04-05       Impact factor: 6.892

5.  The factor structure of the Barratt Impulsiveness Scale (BIS-11) and correlates of impulsivity among outpatients with schizophrenia and other psychotic disorders in Singapore.

Authors:  Jue Hua Lau; Anitha Jeyagurunathan; Saleha Shafie; Sherilyn Chang; Ellaisha Samari; Laxman Cetty; Swapna Verma; Charmaine Tang; Mythily Subramaniam
Journal:  BMC Psychiatry       Date:  2022-03-31       Impact factor: 3.630

6.  Sugars, Alcohol, and Caffeine Intake From Drinks Among Outpatients With Mental Health Disorders in Greece: A Pilot Study.

Authors:  Xenia A Apostolakopoulou; Lamprini Kontopoulou; Georgios E Karpetas; Georgios Marakis; Eleni Vasara; Ioannis G Katsaras; Zoi Maraki; Ioanna V Papathanasiou; Konstantinos S Bonotis
Journal:  Cureus       Date:  2022-01-24

7.  Alcohol Use Disorder and Its Associate Factors Relating to Patients with Severe Mental Disorders Attending Psychiatric Follow-Ups in Northwest Ethiopia.

Authors:  Tilahun Kassew; Mihretu Kiflie; Woredaw Minichil; Ambaye Dejen Tilahun; Bikis Liyew
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-04       Impact factor: 2.570

8.  Associations Between Psychiatric Disorders and Alcohol Consumption Levels in an Adult Primary Care Population.

Authors:  Vanessa A Palzes; Sujaya Parthasarathy; Felicia W Chi; Andrea H Kline-Simon; Yun Lu; Constance Weisner; Thekla B Ross; Joseph Elson; Stacy A Sterling
Journal:  Alcohol Clin Exp Res       Date:  2020-11-05       Impact factor: 3.455

9.  Alcohol use recording in adults with depression in English primary care: a cross-sectional study.

Authors:  Elizabeth Adesanya; Sarah Cook; Elizabeth Crellin; Sinead Langan; Kathryn Mansfield; Liam Smeeth; Emily Herrett
Journal:  BMJ Open       Date:  2022-01-21       Impact factor: 2.692

10.  Aggression Amongst Outpatients With Schizophrenia and Related Psychoses in a Tertiary Mental Health Institution.

Authors:  Anitha Jeyagurunathan; Jue Hua Lau; Edimansyah Abdin; Saleha Shafie; Sherilyn Chang; Ellaisha Samari; Laxman Cetty; Ker-Chiah Wei; Yee Ming Mok; Charmaine Tang; Swapna Verma; Siow Ann Chong; Mythily Subramaniam
Journal:  Front Psychiatry       Date:  2022-01-03       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.